The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

In the 1980s, when Stella Kourembanas, MD, began her career in neonatology, she cared for newborns with pulmonary ...

Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

High-risk acute pulmonary embolism affects around 5% of all pulmonary embolisms and can take a dramatic course even in young ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

A current study involving the University Hospital Bonn (UKB) has investigated which treatment strategy offers the best chances of survival in high-risk acute pulmonary embolism.

"This will allow Koye to develop solutions that help track and treat respiratory health in COPD patients using their voice," said the pharma company in a statement. The two companies plan to ...

has been approved since 2020 in the US as a maintenance treatment used to reduce exacerbations in people living with chronic obstructive pulmonary disease (COPD). Sales of Breztri were $677 ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Personalized Care A nurse practitioner with NYU's pulmonary intervention team chronicles the NSCLC patient experience from diagnosis to ...

An expert discusses the main treatment recommendations of the American Thoracic Society (ATS) guidelines for managing with ...